Infinity Pharmaceuticals Inc. (NASDAQ:INFI) saw a downside of -3.26% to $2.67 after subtracting -$0.09 on Wednesday. The 5-day average trading volume is 1,612,454 shares of the company’s common stock. It has gained $3.04 in the past week. An average of 1,939,153 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,717,223.
INFI’s 1-month performance is -20.46% or -$0.78 on its low of $2.53 reached on 10/08/21. The company’s shares have touched a 52-week low of $1.04 and high of $5.98, with the stock’s rally to the 52-week high happening on 02/11/21. YTD, INFI has achieved 30.19% or $0.57. However, the current price is down -55.35%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Jan 22, 264 days have gone by since the last insider trading activity for Infinity Pharmaceuticals Inc. (INFI). BVF PARTNERS L P/IL (10% Owner) most recently sold 5,848,520 shares at $4.14 per share on Jan 22. This transaction cost the insider $24,205,855.
Infinity Pharmaceuticals Inc. (INFI) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.20 for the sector.INFI stock has a beta of 2.10. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 136.00 while the price-to-book (PB) in the most recent quarter is 5.87.
Infinity Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 9.40, with the current ratio over the same period at 9.40 meaning that INFI stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. In terms of profitability, the gross margin trailing 12 months is 39.70%. The trailing 12-month EBITDA margin is -2211.40%. The firm’s gross profit as reported stood at $40.22 million against revenue of $1.72 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected INFI to announce -$0.14 per share in earnings in its latest quarter, but it posted -$0.13, representing a 7.10% surprise. EBITDA for the quarter stood at more than -$11.13 million. INFI stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 61.06 million, with total debt at $1.69 million. Shareholders hold equity totaling $88.72 million
Let’s look briefly at Infinity Pharmaceuticals Inc. (INFI) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 28.76% to suggest the stock is trending oversold, with historical volatility in this time period at 59.91%.
The stock’s 5-day moving average is $2.77, reflecting a -7.56% or -$0.22 change from its current price. INFI is currently trading -21.11% above its 20-day SMA, -14.06% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +1.13% and +28.71% respectively.
Stochastic %K and %D was 19.16% and 17.63% and the average true range (ATR) pointed at 0.22. The RSI (14) points at 34.80%, while the 14-day stochastic is at 12.95% with the period’s ATR at 0.23. The stock’s 9-day MACD Oscillator is pointing at -0.15 and -0.35 on the 14-day charts.
In the most recent analyst report for Infinity Pharmaceuticals Inc. (NASDAQ: INFI), JP Morgan upgraded it to an Overweight rating. They previously had a Neutral rating on the stock. Analysts offering their rating for INFI stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate INFI as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.
What is INFI’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $14.00, with their median price target at $9.00. Looking at these predictions, the average price target given by analysts is for Infinity Pharmaceuticals Inc. (INFI) stock is $9.29.